| Title |
Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome
|
|---|---|
| Published in |
Cochrane database of systematic reviews, October 2014
|
| DOI | 10.1002/14651858.cd004293.pub3 |
| Pubmed ID | |
| Authors |
Yizhi Chen, Arrigo Schieppati, Xiangmei Chen, Guangyan Cai, Javier Zamora, Giovanni A Giuliano, Norbert Braun, Annalisa Perna |
| Abstract |
Idiopathic membranous nephropathy (IMN) is the most common form of nephrotic syndrome in adults. The disease shows a benign or indolent course in the majority of patients, with a rate of spontaneous complete or partial remission of nephrotic syndrome as high as 30% or more. Despite this, 30% to 40% of patients progress toward end-stage kidney disease (ESKD) within five to 15 years. The efficacy and safety of immunosuppression for IMN with nephrotic syndrome are still controversial. This is an update of a Cochrane review first published in 2004. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 162 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | <1% |
| Unknown | 161 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 23 | 14% |
| Researcher | 22 | 14% |
| Student > Bachelor | 20 | 12% |
| Other | 14 | 9% |
| Student > Postgraduate | 11 | 7% |
| Other | 35 | 22% |
| Unknown | 37 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 73 | 45% |
| Nursing and Health Professions | 13 | 8% |
| Psychology | 8 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 4% |
| Biochemistry, Genetics and Molecular Biology | 5 | 3% |
| Other | 13 | 8% |
| Unknown | 44 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 April 2022.
All research outputs
#7,077,903
of 25,457,858 outputs
Outputs from Cochrane database of systematic reviews
#8,164
of 11,842 outputs
Outputs of similar age
#71,102
of 268,310 outputs
Outputs of similar age from Cochrane database of systematic reviews
#179
of 249 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 11,842 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 38.9. This one is in the 27th percentile – i.e., 27% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 268,310 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 249 others from the same source and published within six weeks on either side of this one. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.